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 OBJECTIVES:  
This study was conducted to determine the incidence of anti-tubercular drug (ATT) induced 
hepatitis and to study the clinical risk factors, clinical, laboratory profile and outcome of patients 
with ATT induced hepatitis. 
METHODOLOGY:  
This case-control study was nested in a cohort of patients from Christian Medical College, 
Vellore. It was carried out from April 2014 to May 2015. All patients newly diagnosed to have 
tuberculosis, started on ATT were eligible for this study. All patients who present with suspected 
ATT related hepatotoxicity were also enrolled in the study. All patients were clinically assessed 
for symptoms of hepatitis at every visit until completion of treatment. Once the patient 
developed ATT induced hepatitis, all hepatotoxic drugs were stopped and a non-hepatotoxic 
regimen was continued. Once the liver function tests normalized, patients were re- introduced 
with first line regimen as per decision of the treating physician and followed up till the 
completion of treatment. The incidence of ATT induced hepatitis was obtained from the cohort. 
The identification of risk factors of ATT induced hepatitis was based on a case control design 
nested in the cohort study. A descriptive study of clinical profile and outcome of patients with 
ATT induced hepatitis was also conducted. The risk factors for ATT induced hepatitis were 
identified by bivariate analysis and logistic regression analysis with odds ratio and 95 % 
confidence interval.   
RESULTS: 
A total of 393 patients were eligible for our study which included 5 patients presenting with ATT 
induced hepatitis. In the cohort, 61% were male and 81% were in the age group 20-59. HIV 
infection was found in 72 patients (18.3%). One hundred and fourteen patients (29%) were 
started on DOTS regimen and the remaining 279 patients (71%) were treated with weight based 
daily regimen. Patients on DOTS regimen had lower rates of HIV infection and disseminated 
disease but had greater undernutrition when compared with patients on daily regimen. Majority 
of the patients (38.9 %) patients had sputum positive pulmonary tuberculosis. A total of 281 
patients (72%) had localized disease and 112 patients (28%) had disseminated disease. Forty 
three patients out of 393 patients developed DILI. The incidence of anti-tubercular drug induced 
liver injury was 9.7 % (95% C.I 7-13.2%) with lower incidence among patients on DOTS 
regimen (DOTS 3.5% (95% C.I 2.4%-4.8%) Vs Daily 14% (95% C.I 7.9 – 22.4%)).  
HIV infection (OR 2.84, p value 0.002, 95% C.I 1.42 – 5.67), daily regimen (OR 4.46, p value 
0.003, 95% C.I 1.55 – 12.81),  disseminated disease (OR 1.769, p value 0.006, 95% C.I 1.23-
2.55),  hypoalbuminemia ( OR 1.92, p value 0.045, 95% C.I 1.01 – 3.68) and chronic liver 
disease (OR 4.72, p value 0.004, 95% C.I 1.5-14.82) were independent risk factors for 
development of drug induced liver injury. On multivariate logistic regression analysis, HIV 
infection, hypoalbuminemia, chronic liver disease and daily regimen were found to be significant 
risk factors for DILI.  A prediction score based on the above risk factors is suggested to identify 
patients who will develop DILI. A score of > 5 will predict DILI with a sensitivity and 
specificity of 74% and 67%.  
Vomiting was the most common symptom seen in 58.1% of patients with drug induced hepatitis 
followed by jaundice in 30.2 % of patients. Four patients developed acute liver failure. The 
majority of patients (77%) developed drug induced liver injury within first 2 months. The mean 
time duration for normalization of liver function was 22 days ranging from 3 to 81 days. Fifteen 
patients (35%) had severe hepatitis. All cause mortality in DILI was 4.7 % (2 patients). 36 
patients (84%) had complete resolution of hepatitis. At least 1 drug was successfully 
rechallenged in 28 out of 29 patients. Rechallenge by both ATS and BTS guidelines had similar 
successful rechallenge. The rates of rechallenge hepatitis were similar in patients who were 
rechallenged according to both ATS and BTS guidelines (13.3% Vs 13% respectively).  
CONCLUSION: 
Incidence of ATT induced hepatitis from our study was 9.7% (95% C.I 7-13.2%) with lower 
incidence among patients on DOTS regimen. HIV infection, daily regimen, disseminated 
disease, hypoalbuminemia and chronic liver disease were independent risk factors for 
development of DILI. Mortality rate was low (4.3%) among patients who developed DILI. 
Rechallenge by both ATS and BTS guidelines had similar successful rate. The predictive scoring 
system proposed from our study needs to be validated by a well designed prospective study. The 
study suggests that the combination of risk factors of extensive TB disease, HIV and 
undernutrition increase the vulnerability to drug induced liver disease particularly with daily TB 
treatment regimen, emphasizing the role of acquired risk factors in the development of DILI. 
 Aim 
 To study the incidence and risk factors of anti-tubercular drugs induced  
hepatitis.  
 To study the profile and outcome of patients with ATT induced hepatitis. 
Objectives 
 
 To determine the incidence of hepatitis among patients on anti-tubercular  
drugs. 
 To study the clinical risk factors for ATT induced hepatitis. 
 To study the clinical and laboratory profile of the patients with ATT induced  
hepatitis. 
 To study the outcome of patients with ATT induced hepatitis. 
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Introduction 
         Tuberculosis (TB) remains a major global health problem. It ranks as the second 
leading cause of death worldwide from an infectious disease, after the human 
immunodeficiency virus (HIV). In India, there were nearly 2.2 million new cases of 
tuberculosis in 2011 and 300,000 TB related deaths in India (2). This is despite the 
availability of treatment that will cure most cases of TB. The first line drugs used for the 
treatment of tuberculosis include Isoniazid, Rifampicin and Pyrainamide all of which are 
hepatotoxic. Incidence of Anti- tuberculosis Drug induced Hepatitis varies from 3 -28% in 
various studies with higher incidence in Asian countries (1). The reason why some people 
develop hepato-toxicity despite all patients receiving the same doses of drugs is unclear. 
Several clinical risk factors have been identified including age, female sex, abnormal baseline 
liver function test (LFT), malnutrition, underlying liver disease, HIV infection and extent of 
tuberculosis. Also genetic susceptibility of the patients to drug liver injury has been identified 
such as NAT2 polymorphism. Despite this knowledge we are not yet able to predict 
development of ATT induced hepatitis before initiation of treatment. Hence we aim to study 
the incidence and risk factors of ATT induced hepatotoxicity so that in future, patients at risk 
can be identified early and serious hepatic complications and death prevented. 
Epidemiology 
             Geographically, the burden of TB is highest in Asia and Africa. India and China 
together account for almost 40% of the world’s TB cases(2).  The most effective anti –
tuberculosis drugs comprises of Isoniazid, Rifampicin and Pyrazinamide all of which are 
hepatotoxic.  ATT induced hepatitis can lead to treatment failure and further contribute to 
Multi Drug Resistant (MDR) tuberculosis as a result of sub-optimal TB treatment regimens. 
Worldwide, 3.7% of new cases and 20% of previously treated cases were estimated to have 
MDR-TB (2). 
Incidence 
              Incidence of ATT induced hepatitis varies from 3 to 28 % as shown in various 
studies. WHO reports show that incidence of ATT induced hepatitis is higher in India and 
China compared to Western countries (2). A meta analysis of 14 published studies from 
western countries showed a ATT induced hepatitis  incidence of 4.38 % (3). One of the 
largest prospective studies was published by Shang (2011) et al from China(4). In that 
population based study, 4304 patients who received DOTS treatment were monitored for 
hepatotoxicity. Only one hundred and six patients developed drug induced hepatitis with an 
incidence of 2.55%.  One possible reason for such a low incidence may be due to DOTS 
regimen which has been shown in other studies to cause lesser drug induced hepatitis than 
daily regimen. 
On the other hand, studies from India showed an incidence of 16% (a study from North India 
by Sharma et al) and 10.5% (In another study by Deepak et al).  The reason for higher 
incidence in India and other South East Asian countries compared to other countries is clearly 
unknown. Possible reasons may be due to ethnic susceptibility, and the presence of more 
clinical risk factors or genetic polymorphisms. 
It is possible that drug induced liver injury may be over diagnosed.  In a  prospective study 
published by Davern et al(5), 318 patients with drug induced liver injury was studied. 50 
patients (16%) tested positive for anti- HEV IgG and 9 patients had developed anti- HEV 
IgM. Out of these patients, 4 patients tested positive for HEV genotype 3. Hence serological 
tests are recommended to rule out acute viral hepatitis if there is high clinical suspicion so 
that unnecessary interruption of treatment can be prevented.   
 
Hepatic adaptation 
 
About 20 percent of patients may have transient elevation in liver enzymes soon after 
initiation of anti-tubercular drugs secondary to hepatic adaptation(6). Exposure of the 
individuals to various drugs can cause physiological adaptive responses.  Genes that regulate 
anti-inflammatory, antioxidant and anti-apoptoptic pathways may be induced which attenuate 
toxin related changes. This may stimulate protective adapation and hepatocyte proliferation. 
Hence asymptomatic transient elevation in liver enzymes may be common, especially alanine 
transaminase (ALT) during the first few weeks after starting treatment which results 
secondary to non-progressive injury to mitochondria and cell membranes. Hence hepatic 
adaptation can be misdiagnosed as drug induced liver injury which can further lead to 
interruption of treatment. Hence differentiating between hepatic adaption and drug induced 
liver injury is essential. Currently there are no laboratory assays available which can 
differentiate both. Hence drug induced liver injury should be diagnosed based on clinical 
features and careful monitoring of liver enzymes. 
Mechanisms of drug induced liver injury 
 
The mechanisms of drug induced liver injury(7) can be classified into three types. 
 Immunological – associated with fever, eosinophilia, rash and abnormal liver 
function tests (classically associated with Rifampicin induced hypersensitivity). 
 Idiosyncratic  
 Dose dependent – for example, isoniazid induced hepatitis.  
Risk factors Studies 
                  Many studies to identify clinical risk factors of developing drug induced liver 
injury have been conducted(8,1,9,10). Risk factors which were  found to be significant from 
those studies  include: demographic factors ( such as age, female sex)(9,11–18), abnormal 
baseline liver function tests(9,12,15,16) , underlying liver disease ( such as Chronic Hepatitis 
B, C infection and significant alcohol intake)(19,14,17,20–22), HIV infection(29–32), 
malnutrition(9,12,16,25,26) and extent of tuberculosis.  Another interesting risk factor which 
was significant in one of the studies was weight loss during treatment. Warmelink et al 
published a retrospective study(27) in British Journal of Nutrition (2011) in which they 
showed weight loss of more than 2 kilograms in the first 4 weeks of treatment was a 
significant risk factor for developing ATT induced hepatitis (Odds ratio 211 95%CI 36-1232 
,p-value < 0·001). However there is no scoring system available till date for predicting ATT 
induced hepatitis to enable careful monitoring and early identification.   
Indian studies 
Indian studies on risk factors for drug induced hepatitis  were published as early as 1981. One 
of those early studies was published by Pande et al which was a case control study from 
AIIMS, Delhi(28).  Eighty six consecutive patients were enrolled and compared against 406 
controls. Older age group, slow acetylators, extensive disease, hypoalbuminemia and high 
alcohol intake were found to be significant risk factors for drug induced hepatitis.  
In a prospective study by Sharma et al published in 2002 ,the incidence of drug induced liver 
injury was 16.5%  (16). Risk factors found to be significant were older age, advanced disease 
and baseline hypoalbuminemia. In another study published by Singla et al,  significant risk 
factors for drug induced liver injury were age more than 35 years, hypoalbuminemia and mid 
arm circumference less than 20 centimeters(29). Risk factors like advanced age, 
hypoalbuminaemia, high alcohol intake, slow acetylator phenotype, and extensive disease 
predisposed the patients to drug induced liver injury according to the study by Pande et 
al(28).  
One of the recent studies from India was published in Journal of Postgraduate Medicine 
(March 2014) by SM Pore from  Maharashtra(30). It was a retrospective study including 893 
patients admitted in a tertiary care hospital from 2005 to 2009. Baseline characteristics 
revealed predominant male population (70%) with mean age of 40 years.  Significant number 
of people had past history of ATT intake (30.36% among cases and 44 % among controls).  
56 patients developed drug induced hepatitis with most of them requiring hospitalization. 
Incidence of drug induced hepatitis from that study was 6.27% which was lower compared to 
other Indian studies.  Significant risk factors for drug induced hepatitis from univariate 
analysis were female gender, past history of ATT intake and alcohol abuse.  However in the 
multivariate analysis, only female gender and alcohol abuse were significant.  Effect of other 
risk factors on drug induced hepatitis like Hepatitis B and C virus infection, pregnancy, 
hypoalbuminemia and malnutrition were not studied probably because of inadequate data.  
Daily versus intermittent DOTS regimen 
Among the various risk factors studied, one of the modifiable risk factors is the 
treatment related risk factor. Both thrice weekly DOTS and daily regimens are commonly 
used in Indian population. Whether daily regimen predisposes the patients more to ATT 
induced liver injury than DOTS regimen is always a concern. There are few studies which 
compared these two regimens worldwide.  In an Indian study (31) published by Mandal et al 
in 2012, administration of daily regimen predisposed the patients more to drug induced liver 
injury as compared to intermittent DOTS regimen (7.5% versus 2.32 %). This study included 
only patients with sputum positive pulmonary tuberculosis and was followed only till 
completion of intensive phase. Both regimens had equal sputum conversion rate at the end of 
intensive phase. However default rate is more in the DOTS group (9.3% versus 5%). 
However we need larger studies and more information about relapse rate before favoring 
DOTS regimen.  
 Genetic susceptibility to Drug induced hepatitis (DIH ) 
                  The variability in susceptibility to drug induced hepatitis despite the similar doses 
raises the issue of genetic susceptibility to drug induced hepatitis. Pharmacogenomic 
variability in drug induced metabolism is well recognized for alcohol, anti retroviral therapy 
and cancer chemotherapy. Could such a mechanism explain the idiosyncratic nature of ATT 
induced hepatitis as well as population based differences?  Various gene based association 
studies revealed ATT related liver Injury susceptibility genes such as N-acetyl transferase 
(NAT2),   Cytochrome P450 2E1 ( CYP2E1), glutathione S transferase M1 (GSTM1) 
glutathione S-transferase T1 (GSTT1)and HLA-DQA1/-DQB1(11,32–39). However they 
also indicate variability between studies and populations.  
Mechanism of Isoniazid and NAT2      
           Anti-tubercular drug induced hepatitis occurs in relation to individual drugs. The 
mechanism of drug toxicity varies for the different anti-tubercular drugs.  This concept is 
elaborated below in relation to Isoniazid.   
Isoniazid (INH) is metabolized by N-acetyl transferase -2 which is involved in phase II 
biotransformation. INH is mainly inactivated by N-acetyltransferase 2 (NAT2) mediated 
acetylation,(40) resulting in acetylisoniazid which is hydrolyzed to acetyl hydrazine and 
isonicotinic acid. Acetyl hydrazine is either hydrolyzed into hydrazine or acetylated into 
diacetylhydrazine, a non-hepatotoxic molecule. A small part of INH is directly hydrolysed 
into hydrazine and isonicotinic acid, and this pathway is greater in slow than in rapid 
acetylators ,  oxidized by cytochrome P450 2E1 (CYP2E1) to form hepatotoxic 
intermediates(41). In slow acetylators, more INH is left for direct hydrolysis into 
hydrazine(42–44);  this also increases the accumulation of acetylhydrazine, which can be 
converted into hepatotoxic intermediates predisposing to liver injury.  
      
Metabolism of Isoniazid 
 
.   
Fig.1 Mechanism of Isoniazid 
               Therefore slow acetylators may be prone to Isoniazid drug induced hepatitis. Also 
among the gene based association studies , NAT2 polymorphism has been definitely 
associated with Isoniazid induced hepatitis (11,34–39,45–48).    NAT2 gene is highly 
polymorphic which is located in the chromosome 8p22. The polymorphism is highly 
attributed to presence or absence of single nucleotide polymorphisms (SNP).  Genetic 
polymorphisms of INH metabolizing enzyme, NAT2 ( N-acetyl transferase 2 (NAT2) have 
been studied which suggest that slow acetylators are more prone to Drug induced hepatitis 
than rapid acetylators (11,34–39,45–48).  
India is known to exhibit vast diversity in socio-ethnic groups. Distinct genetic 
divergence is known to occur between different parts of India. We have known from 
population based studies about the genetic divergence leading to different disease conditions 
like lactose intolerance and sickle cell anemia.  
                Studies that have looked at NAT2 polymorphism show that  incidence of slow 
acetylators among people in  South India was 74 % which is higher compared to other Indian 
studies (according to a South Indian research article by Anitha et al)(49). Another study by 
Bose et al(35) shows that there was higher prevalence of NAT2 slow acetylator genotypes 
among patients with ATT induced hepatitis (70%)  compared to those who did not develop 
hepatitis (44.6 %).  For these reasons, based on the data and samples that we have from this 
study, we are further planning to study the NAT2 genetic polymorphism as a risk factor for 
Isoniazid induced hepatitis as a second phase of this study. 
Types of Hepatitis 
                Drug induced hepatitis is classified based on abnormality of liver function tests and 
severity of hepatitis.  
 The pattern of drug induced hepatitis may be pure enzyme elevation, hepatitis 
or cholestasis.  
 The severity of liver damage may vary from asymptomatic liver enzyme 
elevation to acute fulminant hepatitis and chronic hepatitis. 
Definition of ATT induced hepatitis 
ATT induced hepatitis is defined according to American Thoracic society(6) is defined as  
 Normalization of liver enzymes and resolution of signs and symptoms of 
hepatotoxicity after withdrawal of all anti-TB drugs, and 
 Presence of at least one of the following: 
  A rise to more than 5 times the upper limit of normal (ULN) level of 
liver enzymes 
  Any increase in more than 3 times the upper limit of normal level of 
liver enzymes above pretreatment levels together with anorexia, 
nausea, vomiting, and jaundice. 
This definition is based on development of hepatitis coincident following initiation of anti-
tubercular drugs, normalization of liver function tests after withdrawal of drugs and exclusion 
of other causes of hepatitis ( for example –viral hepatitis ). Since multiple anti-tubercular 
drugs are used simultaneously, it is difficult to identify the incriminating drug except by 
rechallenge.  
Monitoring after initiation of treatment 
The British Thoracic Society and Task Force recommend baseline liver function tests 
before initiation of treatment. The American Thoracic Society do not recommend baseline 
liver function test before starting treatment. Regular monitoring of liver functions tests is 
required in patients with known chronic liver disease.  American Thoracic society 
recommends regular monitoring for patients more than 35 years of age.  
 Management of ATT induced hepatitis 
There are two main approaches to management of ATT induced hepatitis(6,50–52): 
 Reintroduction of full dose of one drug at a time preferably Rifampicin followed by 
Isonizaid and Pyrazinamide ( according to ATS guidelines ). 
 Reintroduction of escalating doses of one drug at a time (according to British 
Thoracic Society guidelines). 
                   Fig. 2 Management ATT induced hepatotoxicity 
             There are few studies which compared different methods of reintroduction of anti-
tubercular drugs.  A study conducted by Sharma et al in a North Indian tertiary hospital 
compared the safety reintroduction of drugs among 3 groups, (Group I – all three drugs at full 
doses simultaneously, Group II – according to ATS guidelines , Group III – according to BTS 
guidelines ). The result of this study was that the recurrence of hepatotoxicity was not 
significantly different between 3 groups(53).  
In August 2014, a prospective study was published from Karachi by Zuberi et al  comparing 
the reintroduction guidelines for anti-tubercular driung induced hepatitis by the British 
Thoracic Society and the American Thoracic Society.  A total of 325 patients who developed 
drug induced liver injury were selected.  Hepatotoxic anti-tubercular drugs were stopped and 
put on alternate non-hepatotoxic regimen.  Once the liver function test normalized, they were 
randomly assigned to reintroduction of ATT according to the American Thoracic Society or 
the British Thoracic Society guidelines.  Primary outcome was the recurrence of ATT 
induced hepatotoxicity following reintroduction.  There was no significant difference in the 
primary outcome between the two groups (16(9.8%) versus18 (11.1 %).  Ease of 
administration was also evaluated on this study which showed that the American Thoracic 
Society guideline was easier to follow. Management of ATT induced liver injury according to 
various guidelines can be summarized as follows:  
Table 1:Summary of management of ATT induced hepatotoxicity based on various 
guidelines 
Authority Monitoring in 
the presence of 
risk factors 
Stopping drugs if 
clinical features of 
hepatitis 
Cut-off levels 
if symptomatic 
(ALT) 
Mode of 
reintroductio
n 
American 
Thoracic 
Society 
 
Yes 
 
Yes 
 
5 times 
 
One drug at a 
time full dose 
British 
Thoracic 
Society 
 
Yes 
 
Yes 
 
5 times 
One drug at a 
time – 
escalating 
doses 
European 
Respiratory 
Society 
 
Yes 
 
Yes 
 
5 times 
 
Hong kong 
tuberculosis 
Service 
 
Yes 
 
Yes 
 
3 times 
 
Outcome of ATT induced hepatitis 
              Reintroduction of anti-tubercular drugs following drug induced hepatitis is often 
successful. In a prospective study conducted in Mumbai by Deepak et al , reintroduction  of 
drugs was successful in 97.4 % of patients(54). This can be possibly explained by hepatic 
adaptation or tolerance to those drugs. He also compared the outcome of patients recruited 
before initiation of treatment with those who presented with ATT induced hepatitis after 
initiation of treatment from another hospital. Among the first group, hepatotoxicity was 
detected earlier than the other group and there were not many hospitalizations, ICU care and 
no deaths. And the mortality rate was 16.6 % in the second group. Hence this study 
emphasizes the importance of monitoring symptoms and liver function tests during treatment 
for early identification of ATT induced hepatotoxicity and prevention of serious 
complications (acute fulminant hepatitis and death).  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Methodology 
 
 
 
 
 
 
 
 
 
 
Design: 
  This case-control study was nested in a cohort of Department of General Medicine 
wards and Out-patients and DOTS clinic patients (Community Health and Development) of 
Christian Medical College, Vellore. It was carried out from April 2014 to May 2015. The 
study protocol was approved by Institutional Ethics Review Board, Christian Medical 
College, Vellore.  Informed consent was obtained from the patients recruited in the study. 
Case Definition 
 
In this study, anti-tubercular drug induced Hepatitis was diagnosed according to American 
Thoracic Society definition(6): 
1. Normalization of liver enzymes and resolution of signs and symptoms of 
hepatotoxicity after withdrawal of all anti-TB drugs, and 
2.  Presence of at least one of the following: 
 A rise to more than 5 times the upper limit of normal (ULN) level of 
alanine transaminase (ALT) and/or aspartate transaminase (AST)  
  Any increase in more than 3 times the upper limit of normal level of AST 
and/or ALT above pretreatment levels together with anorexia, 
nausea,vomiting, and jaundice. 
If the LFT returned to normal after stopping hepatotoxic drugs,  the hepatitis was attributed to 
hepatotoxic drugs. 
In patients who liver enzymes did not normalize even after stopping ATT, subsequent blood 
tests was done to rule out Acute viral hepatitis ( A,B and E). 
 
 
Enrollment: 
All patients who were newly diagnosed to have tuberculosis and undergoing treatment 
in the respective units were enrolled in this study after a written consent by the principal 
investigator.  Detailed history and clinical examination were done at baseline for all the 
recruited patients.  All the relevant clinical data including age, gender, height, weight, site of 
tuberculosis, mode of diagnosis, extent of tuberculosis, alcohol ingestion underlying liver 
disease, presence of co-existent HIV infection, diabetes mellitus were recorded in the patient 
enrollment proforma (See Appendix) . Baseline laboratory tests were performed including 
blood sugars, liver function tests, hepatitis B surface antigen (HBsAg), anti-hepatitis C 
antibody (HCV antibody) and HIV ELISA.  Enrollment of patients from DOTS clinic 
(CHAD) and follow up were done with the help of co-investigator.  
Eligibility criteria  
All patients newly diagnosed to have tuberculosis, started on anti-tuberculosis 
treatment and being followed up in General Medicine Outpatient and Inpatient Department in 
Christian Medical College, Vellore and patients who were started on DOTS treatment at the 
Community Health and Development (CHAD) hospital which is part of the Community 
Health department were eligible for this study. All patients who present with suspected ATT 
related hepatotoxicity (diagnosed and started on treatment in another hospital) were also 
enrolled in the study. 
Exclusion criteria 
 Patients with abnormal baseline LFT (increased enzymes or bilirubin). 
 Patients who did not give informed consent. 
 
Cases and Controls 
All the patients who developed anti-tubercular drug induced hepatitis were classified as group 
A. The control group consisted of patients on treatment who did not show any evidence of 
anti-tubercular drug induced hepatitis, selected from the same cohort. All controls as defined 
above were classified as group B. All patients who presented with suspected ATT related 
hepatotoxicity (diagnosed and started on treatment in another hospital) were included in the 
study as Group C.  
The incidence of ATT induced hepatitis was obtained from the cohort. The identification of 
risk factors of ATT induced hepatitis was based on a case control design nested in the cohort 
study. A descriptive study of clinical profile and outcome of patients with ATT induced 
hepatitis was also conducted. 
Diagnosis of tuberculosis 
 
Mode of diagnosis varied depending upon the suspected site of tuberculosis: 
 Pulmonary Tuberculosis was classified as follows: 
 Sputum positive if sputum smear showed Acid fast Bacilli 
 Sputum negative if AFB smears were negative but symptoms and radiological 
features were suggestive of tuberculosis. 
  Tuberculosis meningitis was diagnosed as PRESUMPTIVE (based on duration of 
illness, CSF findings ( lymphocytic pleocytosis with increased protein and low sugar 
and radiological features) or DEFINITE (also positive culture). 
 Pleural and peritoneal tuberculosis was diagnosed based on fluid analysis and /or 
caseating granulomas on histology or positive culture. 
 Tuberculosis of the lymph node was diagnosed based on imaging, caseating 
granulomas on histology or positive culture 
 Tuberculosis of bone and spine was diagnosed based on histopathology / culture 
from the suspected area. 
 Genitourinary tuberculosis was diagnosed based on positive urine AFB smear and 
/or culture. 
  Disseminated tuberculosis was defined as radiological features of military or 
involvement of 2 or more different sites. 
Patients who were empirically started on anti-tubercular treatment were also included in the 
study. 
Follow-up of patients on treatment 
All patients who fulfilled the inclusion criteria were enrolled by the principal 
investigator after the informed consent.  Patient enrollment form was filled by the principal 
investigator. 
In this cohort, patients on anti-tuberculosis treatment were followed up regularly as follows.  
All patients were clinically assessed for symptoms of hepatitis at every visit until completion 
of treatment by the treating physician. All patients were educated regarding the clinical 
features of hepatitis (anorexia , nausea , vomiting and jaundice )  and report  immediately if 
they develop so.  
 All the treating physicians were informed in person and given an electronic alert 
through Clinical workstation (Electronic Medical Record System of Christian Medical 
College) to inform the Principal investigator if patients develop ATT induced 
hepatitis. When the patient was being seen by the treating doctor, an electronic alert 
appears on the screen requesting them to contact the Principal Investigator. 
 Investigations and OP visits of the patients were electronically tracked using the 
Clinical workstation (CMC EMR) by the principal investigator every 2 weeks or more 
frequently if needed. If patients developed ATT induced hepatitis, the principal 
investigator was contacted by the treating physician. 
 Once the patient developed ATT induced hepatitis, he/she was regularly followed up 
by the principal investigator in every OP visit till the completion of treatment. 
 Detailed assessment of patients, review of OP chart notes and filling up proforma was 
done by the Principal Investigator. 
 All the patients who had lost to follow up were contacted later by the principal 
investigator through telephone. The reasons for lost of follow up, treatment history 
and complication related to treatment were obtained. 
Severity of hepatitis 
The degree of severity of hepatotoxicity was assessed by the peak level of serum 
transaminases  and classified according to the World Health Organization Toxicity 
Classification Standards(6). 
Mild          - Elevations of AST and/or ALT to 3–5 times the ULN (121– 200 UI/l) 
Moderate - 5–10 times the ULN (201–400 UI/l) 
Severe      - 10 times the ULN (>400 UI/l). 
Type of hepatitis 
 
It was sub-classified as follows: 
 Anicteric hepatitis  
       Elevation of liver enzymes without increase in bilirubin levels 
 Icteric hepatitis        
              Elevation of  liver enzymes with increase in bilirubin levels. 
 Drug induced cholestasis 
              Direct hyperbilirubinemia without increase in liver enzymes. 
 Drug induced hepatitis with hepatic decompensation  
              Prolonged PT, low albumin, ascities, encephalopathy 
Risk factors (predictors) of DILI 
   
 The clinical risk factors were assessed as follows :  
               Age, sex, BMI, underlying liver disease , HIV infection,  significant alcohol intake, 
site and severity of illness, abnormal LFT during initiation of treatment, pregnancy, MDR 
tuberculosis, past history of anti tubercular treatment, DOTS regimen versus daily regimen. 
 Genetic : 
            NAT2 polymorphism (to be studied subsequently). 
All patients who were diagnosed to have Anti-tuberculosis drug induced hepatitis had the 
proforma section on drug induced hepatitis filled up. The diagnosis of drug induced liver 
injury was made as defined above. All hepatotoxic drugs were stopped and a non-hepatoxic 
regimen was continued.   
Reintroduction of drugs after Drug induced liver injury 
       Once the liver function tests normalized (at least enzymes less than 2 times the upper 
limit of normal), patients were re- introduced with first line regimen. The treating physician 
decided regarding mode of re-introduction, either full dose of one drug at a time or an 
escalating dose introduction or all the three drugs together.  
Once the drug was re-introduced, the patients were closely monitored for clinical features of 
hepatitis and regular monitoring of LFT was done. If symptoms recurred or LFT 
abnormalities increased, the last drug added was stopped. 
At Christian Medical College, Pyrazinamide(PZA) was usually started after Rifampicin(RIF) 
and Isoniazid(INH). If RIF and INH were tolerated, and hepatitis was severe, it was assumed 
that PZA was the responsible drug and rechallenge with this drug was generally avoided. 
However the choice of order of reintroduction was decided by the treatment physician.   
 Identifying the likely drug that induced drug induced hepatitis 
If reintroduction of a particular drug resulted in increase in liver enzymes, then that 
drug was likely to be the cause of drug induced hepatitis.  
 In case if the patients did not tolerate all three drugs during reintroduction, the drug which 
caused hepatotoxicity initially was unknown (Group X) 
In case re-challenge of drugs did not take place (for example underlying chronic liver disease 
or failure of normalization of LFT), then again the incriminating drug cannot be identified 
(Group X) 
 Outcome of patients with ATT induced hepatitis 
 
The outcomes measures were defined in terms of Tuberculosis and Hepatitis.  
 
The hepatitis outcome were measured as follows :   
 Severity of hepatitis and type of hepatitis (see definitions)  
 Time period for normalization of LFT 
 Requirement of hospitalizations and ICU care 
 Case fatality 
 Number of first  line drugs successfully reintroduced 
 
  
The outcome of tuberculosis were measured as  
 whether the patient had completed the treatment course  
 whether the patient was cured of tuberculosis ( For example,  improvement of clinical 
features in TB meningitis or sputum AFB negativity and improvement in  Chest X ray 
in patients with Sputum Positive Tuberculosis or resolution of TB pleural effusion as 
seen in Chest X ray) 
 Duration of treatment  
 rechallenge regimen used. 
 Sample size calculation 
 
Sample size was calculated as follows: 
 For the incidence of ATT induced hepatitis, the sample size was calculated from the 
following study: 
Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK. Evaluation of clinical and 
immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. 
Am. J. Respir. Crit. Care Med. 2002 Oct 1;166(7):916–9.                  
         Sample Size = 4pq/d
2 
             p = 16% d=3 
   Sample Size calculated = 600  
 Clinical Risk factors  
The sample size was calculated as per the formula for the case – control study. The 
power of the study was taken as 80% with alpha error of 5 %. The following study 
was chosen for calculation of sample size.  
 
One of the significant risk factor for ATT induced hepatitis shown in the previous 
study was baseline hypoalbuminemia (albumin<3.5g/dl) before initiation of treatment. 
The sample size was calculated by the following formula: 
Sample size  = (Zα + Zβ)2 2p *q /(p1-p2)2 
 The sample size calculated was 220. 
Statistical methods 
Incidence of ATT induced hepatitis was calculated from the cohorts with 95% 
confidence interval. The risk factors for ATT induced hepatitis will be identified by bivariate 
analysis and logistic regression analysis with odds ratio and 95 % confidence interval.  A P-
value less than 0.05 are considered significant. A Z-value greater than 1.96 is considered 
significant at 95% confidence interval.If the event rate is less than 10%, then LR analysis 
with log link will be done. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Results  
 
 
 
 
 
 
 
 
 
 
 
A total of three hundred and ninety three patients who were initiated on anti-TB treatment 
were eligible for our study. They were recruited in the Department of General Medicine 
wards and Out-patients and DOTS clinic patients (Community Health and Development 
hospital) of Christian Medical College, Vellore. This study was carried out from April 2014 
to May 2015. 14 patients were excluded from the study since they did not give consent. Out 
of 393 patients, 5 patients presented to the hospital with drug induced liver injury and 
classified as Group C.  Remaining 388 patients belonged to the cohort of patients with newly 
diagnosed with tuberculosis who were initiated on anti-TB treatment.   
Strobe Figure 
 
 
 
 
 
 
  
                  
Fig.3 STROBE Figure 
 
 
407 patients assessed for 
eligibility 
393 patients eligible and enrolled 
14 patients did not give 
consent 
388 patients were newly 
diagnosed with tuberculosis 
(Group A &B) 
5 patients presented with drug 
induced liver injury (Group C) 
 Baseline characteristics of the patients 
Out of 393 patients, 308 patients were enrolled from the Department of General 
Medicine, Christian Medical College Hospital (CMC), Vellore and 85 patients from the 
DOTS clinic at Community Health and Department hospital, CMC Vellore.  
Fig.4 Gender distribution of the patient cohort 
 
In the cohort of 393 patients, 241 patients (61%) were male and 152 patients (38%) were 
female (Fig.4). 
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 Fig. 5 Age distribution of the patient cohort 
Most of the patients (81%) were in the age group 20-59. Twenty three patients (6%) belong 
to younger group while 52 patients (13%) belonged to older age group (Fig.5). Data on Body 
mass index was available for 362 patients . One hundred and seventy six patients (45%) had 
normal body mass index, and 134 patients (34 %) of enrolled patients had a low body mass 
index (<18.5) and 50 patients (15%) were overweight at enrollment (Fig. 6).  
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 Fig.6 Body mass index (BMI) of the patient cohort. 
HIV infection was found to be positive in 42 patients. Diabetes mellitus was present in 97 
patients (24.7%).Among diabetic patients, mean HbA1c was 8.7 % suggesting uncontrolled 
diabetes at the time of diagnosis. HbA1c measurements ranged from 5.1 to as high as 14.6 %.  
Risk factors for developing chronic liver disease were also studied in this cohort such as 
hepatitis B and C and history of alcohol intake. Detailed history of significant alcohol intake 
could not be obtained from all the patients. A hundred patients (25.4%) had at least one risk 
factor for developing chronic liver disease. History of alcohol intake (both current and past) 
was documented in 93 patients (23.7%). However clinical features of chronic liver disease 
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were present only in 14 patients (3.6%).  Twenty three patients (5.9%) had past history of 
jaundice (Table 2). Among 390 patients, (9.4%) of them had past history of intake of anti-
tubercular drugs. One hundred and fourteen patients (29%) were started on DOTS regimen 
with majority of patients enrolled from Community Health and Development (CHAD) DOTS 
clinic. The remaining patients (71%) were treated with weight based daily regimen from the 
Medicine outpatient department. 
   Table 2.Baseline characteristics of patients 
 Number of patients  Percentage (%)  
Diabetes mellitus  97  24.7  
HbA1c  Mean-8.75 % (Range 5.1-14.6)  
Hypoalbuminemia  177  45.0  
HIV infection 72  18.3  
Risk factors for liver disease  100  25.4  
Alcohol intake  93  23.7  
Chronic liver disease  14  3.6  
Past history of jaundice  23  5.9  
Pregnancy  1  .3  
Past history of ATT intake  37  9.4  
DOTS regimen 114 29 
Daily regimen 279 71 
 
 
Comparison of baseline characteristics of patients on daily and DOTS regimen 
While comparing the patients on daily and DOTS regimen, mean age and gender distribution 
were similar.  More patients on DOTS regimen (97.4%) had localized disease when 
compared with patients on daily regimen (33%). HIV infection was more commonly seen in 
patients on daily regimen (22.4% Vs 8.8%). Fifty one percent of patients on DOTS regimen 
were underweight when compared to daily regimen (33%). Other baseline characteristics 
were similar in both groups. To summarize, patients on DOTS regimen had lower rates of 
HIV infection and disseminated disease but had greater undernutrition when compared with 
patients on daily regimen. 
Table 3: Baseline characteristics of patients on daily and DOTS regimen 
 Daily (%) DOTS (%) 
Age(mean) 41.7 40.4 
Sex 
Male 
Female 
 
167(60) 
112(40) 
 
 
74(65) 
40(35) 
BMI 
Under weight 
Normal weight 
Obese 
 
90(33) 
141(52) 
41(15) 
 
46(51) 
35(39) 
9(10) 
Extent 
Local 
Disseminated 
 
170(61) 
109(39) 
 
111(97.4) 
3(2.6) 
Diabetes Mellitus 65(23%) 32(28%) 
HIV infection 62(22.4%) 10(8.8%) 
Alcohol intake 50(18%) 33(29%) 
Hepatitis B 5(1.8%) 3(2.6%) 
Chronic Liver Disease 13(4.7%) 1(1%) 
Past history of jaundice 18(6.5%) 5(4.4%) 
Hypoalbuminemia 133(49%) 44(39%) 
Past history of ATT intake 35(12.6%) 2(6.5) 
Diagnosis and Extent 
Majority of the patients (38.9 %) patients had sputum positive pulmonary 
tuberculosis. 101 patients (25.7%) had disseminated tuberculosis and 54 (14%) patients had 
tuberculous meningitis. Different sites of tuberculosis are summarized below in the table 4.
 Table 4 Distribution of tuberculosis according to anatomical site 
Site of TB Number of 
patients 
Percentage (%) 
Sputum positive pulmonary 153 38.93 
Disseminated 101 25.70 
Meningitis 54 13.74 
Lymphadenitis 35 8.91 
Pleural effusion 13 3.31 
Sputum negative pulmonary 9 2.29 
Peritonitis 7 1.78 
Spine 6 1.53 
Osteomyelitis 5 1.27 
Central nervous system 3 0.76 
Synovitis 3 0.76 
Others 2 0.51 
Miliary  1 0.25 
Genito urinary 1 0.25 
Among 393 patients in our cohort, 281 patients (72%) had localized disease and 112 patients 
(28%) had disseminated disease (fig.7). 
  
 
Fig. 7 Extent of tuberculosis in the patient cohort 
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  Fig.8 Method of confirmation of TB diagnosis in patient cohort (393 patients) 
Diagnosis was made based on microbiological basis in most of the patients (66.9%). This was 
followed by histopathology, lab, radiological and clinical diagnosis respectively (Fig.8).  
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Risk factors for liver disease 
 
Two hundred and ninety three patients (74.6 %) did not have any known risk factors 
for chronic liver disease of alcohol use, Hepatitis B or C infection. History of alcohol intake 
was present in 83 patients (21.1%). However quantification of alcohol intake could not be 
obtained in all the patients. Hepatitis B and C infection were present in 8 and 2 patients 
respectively. 
Table 4.Risk factors for chronic liver disease in patient cohort 
  
Risk factors 
 
Number of patients 
 
Percentage % 
None 293 74.6 
Alcohol intake 83 21.1 
Hepatitis B 8 2 
Hepatitis C 2 0.5 
Others 4 1 
 
TB PCR and Microbiological culture 
 
Gene Xpert TB PCR was done in 234 patients out of whom 142 patients (47 %) had 
positive results. Rifampicin resistance was not detected in 116 patients (84 %) where as in 16 
patients (12%), rifampicin resistance was detected (Fig.9). 
 
  
 Fig.9 Rifampicin resistance according to Gene Xpert TB PCR in patient cohort 
 
Mycobacterial culture was done in 275 patients out of whom 120 patients (39 %) had positive 
culture (fig.8). Of 95 patient with drug succeptibility testing results, 67 patients (70.5% had 
Pan-susceptible tuberculosis and 28 (29.5%) had drug resistant Mycobacterium tuberculosis. 
Eleven patients had MDR tuberculosis . Four patients had XDR tuberculosis. Izoniazid 
monoresistance was seen in 8 patients (2.6% ) and rifampicin monoresistance in 2 patients. 
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    Fig. 10.Microbiological ssceptibility results among patient cohort 
 
Current status and follow up 
All patients were followed up till 1
st
 week of August 2014. A hundred and eight 
patients (29%) had successfully completed treatment and cured.  A hundred more patients are 
still under treatment. One hundred and twenty eight patients (34.4%) had lost follow up in 
our hospital (fig.11). Mortality rate was 7.5% (28 patients). Six patients were referred to local 
DOTS centre for continuation of treatment.  
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    Fig.12 Current status of TB outcomes in patient cohort 
Incidence of drug induced liver injury 
During follow up, 43 patients developed anti-tubercular drug induced liver injury 
during the course of treatment.  The incidence of drug induced liver injury was calculated 
after excluding the patients from Group C . 
Hence after excluding these five patients, 38 patients out of 388 patients from the 
cohort developed drug induced liver injury while on treatment. Therefore incidence of anti-
tubercular drug induced liver injury was calculated as 9.7 %. 
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Incidence of ATT induced hepatitis = 38/388 = 9.7% (95% C.I 7-13.2%) 
Incidence in DOTS regimen 3.5% (95% C.I 2.4%-4.8%) 
Incidence in daily regimen 14% (95%C.I 7.9 – 22.4%) 
Predictors of Drug induced liver injury (DILI) 
 
Predictors of drug induced liver injury (DILI) were classified into three categories   
1) Patient related background factors 
2) Disease related 
3) Treatment related  
Background factors   
 Gender 
 Age 
 BMI 
 Hypoalbuminemia  
 Liver disease 
 Alcohol intake 
 Past history of jaundice 
 Past history of ATT intake 
 Pregnancy 
 Genetics like NAT2 polymorphisms 
Disease related 
 Local or disseminated disease 
 HIV co-infection 
 
Treatment related  
 DOTS versus daily regimen 
Gender 
There was no significant difference in gender between cases and controls (p value 
0.14). In few published studies, female gender was found to be significant risk factor for drug 
induced hepatitis(28). However in our study, gender was not a significant risk factor. 
Table 5: Gender distribution and DILI 
Gender  DILI (%)   No DILI(%)  Odds Ratio  95% C.I.  
Male  22(51)  219(63)  0.627  0.332 -1.184  
Female  21(49)  131(37)  p-value 0.147   
 
Age 
Table 6: Age distribution and development of DILI 
Age  DILI (%)  No DILI (%)          
< 19  4 (9)  19(5)  
20-59  34(79)  284(81)  
> 60  5(12)  47(14)                 p-value 0.578 
 
Age of the cohort was divided into 3 groups – younger, middle age and older age group.  
However age was not a statistically significant risk factor on bivariate analysis to cause drug 
induced hepatitis (p value – 0.578). 
Older people are more prone to drug induced liver injury according to previous studies. 
Hence further analysis was done comparing older age group with all patients <60 years. Still 
there was no significant association between age and DILI (p value 0.742). 
Table 7: Older age group and development of DILI 
Age  DIlLI(%)  No DILI (%)          Odds Ratio    95% C.I 
< 60 38(88)  303(87)  1.18 0.44-3.15 
>=60 5(12)  47(13)  p-value 0.742  
 
 
Body mass index 
 
Literature review revealed that patients who are underweight are more predisposed to ATT 
induced hepatitis. In our study group, there was no statistically significant association 
between BMI and DILI (p value – 0.257). 
Table 8: Body mass index and development of DILI 
Body mass index DILI (%) No DILI (%) 
Under weight (<=18.5)  15 (36) 121 (38) 
Normal Weight (18.5 - 24.9)  18 (43) 158 (49) 
Obese (>=25)  9 (21) 41 (13)        p-value 0.257 
 
Further analysis comparing patients who were underweight (<18.5) and all other patients did 
not show any significant association between weight and DILI (p value 0.792).  
Table 9 Underweight and developmental of DILI 
Body mass index DILI(%) No DILI (%) Odds Ratio     95 %C.I 
Under weight 
(<=18.5)  
15 (36) 121 (38) 0.91 0.47-1.79 
Others (>=18.5)  27 (64) 199(62) p-value 0.792  
  Similarly obesity was not found to be a significant variable in the development of  
DILI ( p value 0.655). 
Table 10 Obese patients and development of DILI 
Body mass index DILI (%) No DILI (%) Odds Ratio   95 %  C.I 
Others(<=24.9)  33(79)  279 (87) 0.81 0.32-2.05 
Obese (>=25)  9 (21) 41(13) p-value 0.655  
 
Past history of ATT intake 
 
Table 11 Past history of ATT intake and development of DILI 
Past ATT 
intake 
DILI (%) No DILI (%) Odds Ratio 95 %C.I 
Yes 8(19) 29(11) 1.86 0.79-4.39 
No  35 (81) 236 (89) p-value 0.152  
In patients with drug induced liver injury, 8 (19%) had past history of ATT intake whereas 29 
(11%) patients had past history of ATT intake in control group. Prior ATT was not a 
statistically significant risk factor for development of DILI (  p value 0.15). 
Past history of jaundice 
Twelve percent of cases of DILI had past history of jaundice when compared to 5% of the 
patients who did not develop DILI. Though this variable was not significant ( p value - 
0.087),  odds ratio was 2.43 suggesting it was close to being significant. 
Table 12 Past history of jaundice and development of DILI 
Past history of jaundice DILI(%) No DILI (%) Odds Ratio 95 %C.I 
Yes 5 (12) 18 (5) 2.43 0.85-6.91 
No  38 (88) 332  (95) p value0.087  
 
Hypoalbuminemia 
Hypoalbuminemia was significantly associated with the development of DILI. Sixty 
percent of DILI cases had hypoalbuminemia when compared to 44% of the controls who did 
not develop DILI ( p value -0.045, OR1.92, 95%CI 1.01 – 3.68).  
Table 13 Hypoalbuminemia and DILI 
Hypoalbuminemia DILI (%) No DILI (%) Odds Ratio 95 %C.I 
Yes 26 (60) 151 (44) 1.92 1.01-3.68 
No 17 (40) 190 (56) p-value 0.045  
 
HIV infection 
Thirty six percent of DILI cases had HIV infection when compared to 16 % of the 
controls (without DILI) who had HIV infection. Hence HIV infection was found to be a 
significant risk factor for development of DILI. (p value 0.002 ,OR 2.84 , 95 % C.I  1.42-
5.67). 
Table 14 HIV infection and development of DILI 
HIV DILI(%) No DILI (%) Odds Ratio C.I 
Yes 15 (36) 57 (16) 2.84 1.42-5.67 
No  27 (64) 291 (84) p-value 0.002  
 
Site of tuberculosis 
Diagnosis was grouped into two categories: 
 Disseminated and severe extra pulmonary disease  
 Pulmonary and non severe extra pulmonary disease.  
The incidence of DILI is pulmonary and non severe extrapulmonary TB was – compared to – 
in patients with disseminated and severe extrapulmonary TB.  Disseminated and severe 
extrapulmonary TB  group was a significant risk factor for drug induced hepatitis (70% Vs 
44%, p value 0.001, OR 2.971,95 % CI 1.49-5.89).  
Table 15  Diagnosis and Development of DILI 
Diagnosis DILI (%) No DILI (%) Odds Ratio 95% C.I 
Disseminated / 
Severe EP 
30 (70) 
 
153(44) 
 
2..971 1.49-5.89 
Pulmonary / 
Non severe EP 
13 (30) 197 (56) p-value 0.001  
 
 
 
Regimen 
The only modifiable variable among various risk factors is the treatment related factor.  
DOTS and daily regimen was compared among cases and controls.   
Table 16 Regimen and development of DILI 
Regimen  DILI (%)  No DILI (%)  Odds Ratio  95%C.I.  
Daily  39(14)  240(86)  4.469  1.558-12.814  
DOTS  4(3.5)  110(96.5)  p-value 0.003  
 
Fourteen percent of patients on daily regimen developed jaundice as compared to only 3.5% 
of patients on DOTS regimen (p value 0.003, OR 4.469, 95% CI 1.56-12.81). Daily TB 
treatment regimen is significantly associated with development of DILI with an odds ratio of 
4.469. 
 
Risk factors for liver disease 
Table 17 Risk factors for liver disease and development of DILI 
Risk factor for 
Liver Disease 
DILI (%) No DILI (%) Odds Ratio C.I 
Yes 12 (28) 88 (25) 1.15 0.57-2.34 
No  31 (72) 262 (75) p-value 0.695  
 
Risk factors for liver disease assessed in our study are alcohol intake, hepatitis B and hepatitis 
C infection. Twenty eight percent of the DILI group had risk factors for liver disease when 
compared to 25% of the patients who did not develop DILI. This difference was not 
statistically significant (p value 0.695%). 
Chronic Liver disease (CLD) 
14 patients had underlying chronic liver disease. The incidence of DILI in patients who had 
chronic liver disease was 12 % when compared to 2.7% of patients who did not have chronic 
liver disease.  Hence presence of chronic liver disease was significant risk factor for DILI 
(with p value of 0.004 and OR of 4.72). 
Table 18 Chronic liver disease and development of DILI 
CLD DILI (%) No DILI (%) Odds Ratio 95 %C.I 
Yes 5 (12) 9 (2.7) 4.72 1.50-14.82 
No 38(88) 323 (97.3) p-value 0.004  
 
Extent of tuberculosis disease 
 Disseminated disease was significantly associated with the development of DILI 
(46.5 % versus 26 %, p value – 0.006, OR 1.769, 95% CI 1.23- 2.55). 
Table 19 Extent and development of DILI 
Extent DILI (%) No DILI (%) Odds Ratio 95%C.I 
Local  23 (53.5) 258 (74) 1.769 1.23-2.55 
Disseminated  20 (46.5) 92  (26) p-value 0.006  
 
 
 
Pregnancy 
Only one patient was pregnant among the cohort. Hence risk factor analysis was not 
appropriate for this patient.  
Table 20 Pregnancy and development of DILI 
Pregnancy Cases (%) Controls (%) Odds Ratio 95 %C.I 
Yes 0(0) 1(.3) 0.0 0.0 
No  43(100) 349(99.7) p-value 0.726  
     
 
History of alcohol intake 
 
Table 21 History of alcohol intake and development of DILI 
History of alcohol 
intake 
DILI (%) No DILI (%) Odds Ratio 95%C.I 
Yes 9 (21) 84 (24) 1.19 0.55-2.59 
No  34 (79) 266 (76) p-value 0.655  
 
 History of alcohol intake (both current and past) was not a statistically significant predictor 
of liver injury. However detailed quantification of alcohol intake could not be obtained from 
the patients.  
Summarizing, clinical significant predictors of ATT induced hepatitis according to bivariate 
analysis were HIV infection (OR 2.84), hypoalbuminemia (OR 1.92), underlying chronic 
liver disease (OR 4.72), daily regimen (OR 4.47) and extent of tuberculosis (OR 1.8). 
Multivariate logistic regression analysis for risk factors for 
development of drug induced hepatitis 
 
Multivariate logistic regression analysis was done according to three models which were 
discussed earlier.  The models analyzed are as follows: 
 Model1 – Patient related background variable 
 Model 2 –Disease and treatment related variable 
 Model 3 – All factors together 
The above mentioned models form the conceptual framework(55). This concept was 
originally drafted by WHO in 2005. This framework for analysis has a conceptual orientation 
based on potential mechanisms of hepatotoxicity (background variables, TB disease variables 
and TB treatment variables) . This framework shows how major determinants relate to each 
other and helps us in better understanding of different determinants. Similar framework has 
been  used in an article published by Patel et al in the Journal of Epidemiology(56).  
 
 
 
 
 
 
 
 
Table 22   Model 1 including background variables 
 
Risk factor 
Variables 
Unadjusted Analysis (N =393 ) Adjusted Analysis 
Case  
p 
value 
No DILI DILI OR 95 % CI p 
value N % N % 
Gender : 
     Male 
     Female 
 
219 
131 
 
63 
37 
 
22 
21 
 
51 
49 
 
 
0.14 
 
 
1.77 
 
 
0.85-3.7 
 
 
0.12 
Age: 
    <=19 
    20-59 
     >60 
 
19 
284 
47 
 
5 
81 
14 
 
4 
34 
5 
 
9 
79 
12 
 
 
0.57 
 
 
0.627 
 
 
0.27-1.4 
 
 
0.27 
CLD :Yes 
           No 
9 
323 
3 
97 
5 
38 
12 
88 
 
0.004 
 
3.78 
 
1.12-12.77 
 
0.032 
Hypoalbuminemia 
Yes 
No 
 
151 
190 
 
44 
56 
 
26 
17 
 
60 
40 
 
0.045 
 
2.04 
 
1.01-4.1 
 
 
0.046 
BMI 
Under weight 
Normal Weight  
Obese 
 
121 
158 
41 
 
38 
49 
13 
 
15 
18 
9 
 
36 
43 
21 
 
 
0.257 
 
 
1.42 
 
 
0.87-2.32 
 
 
0.159 
Alcohol Intake 
Yes 
No 
 
266 
84 
 
76 
24 
 
34 
9 
 
79 
21 
 
0.65 
 
1.19 
 
0.47-2.9 
 
0.70 
 
In the model 1 which included background variables, significant predictors of drug induced 
liver injury were hypoalbuminemia and chronic liver disease with OR of 2 and 3.8 
respectively. 
Table 23   Model 2 including disease and treatment variables 
 
In the model 2 which examined disease and treatment variables, daily regimen and HIV co-
infection were found to be significant predictors. Disseminated disease which was very 
significant (0.006) during bivariate analysis was not significant during multivariate analysis..  
 
 
Risk factor 
Variables 
Unadjusted Analysis (N = 393 ) Adjusted Analysis 
Case  
p value No DILI DILI OR 95 % CI p value 
  
n % n % 
HIV 
Yes 
No 
 
57 
236 
 
16 
89 
 
15 
35 
 
36 
81 
 
0.002 
 
2.14 
 
1.03-4.45 
 
0.04 
Regimen 
Daily 
DOTS 
 
240 
110 
 
69 
31 
 
39 
4 
 
91 
9 
 
0.003 
 
3.23 
 
107-9.7 
 
0.037 
Extent 
Local 
Disseminated 
 
258 
92 
 
74 
26 
 
23 
20 
 
53 
47 
 
 
0.006 
 
 
1.5 
 
 
0.75-3.1 
 
 
0.23 
Table 24 - Model 3 All risk factors for DILI together 
 
Risk factor 
Variables 
Unadjusted Analysis (N =393) Adjusted Analysis 
Case  
p 
value 
No DILI DILI OR 95 % CI p value 
n % N % 
Gender : 
     Male 
     Female 
 
219 
131 
 
63 
37 
 
22 
21 
 
51 
49 
 
 
0.14 
 
 
1.94 
 
 
0.89-4.2 
 
 
0.09 
Age: 
     <=19 
    20-59 
    >=60 
 
19 
284 
47 
 
5 
81 
14 
 
4 
34 
5 
 
9 
79 
12 
 
 
0.57 
 
 
0.71 
 
 
0.29-1.7 
 
 
0.46 
CLD 
Yes 
No 
 
9 
323 
 
3 
97 
 
5 
38 
 
12 
88 
 
0.004 
 
3.50 
 
1.01-
12.05 
 
0.04 
Hypoalbuminemia 
Yes 
No 
 
151 
190 
 
44 
56 
 
26 
17 
 
60 
40 
 
0.045 
 
1.5 
 
0.73-3.1 
 
0.25 
HIV :Yes 
          No 
57 
236 
16 
89 
15 
35 
36 
81 
 
0.002 
 
2.19 
 
0.99-4.7 
 
0.05 
BMI 
Under Weight 
Normal Weight 
Obese 
 
121 
158 
41 
 
38 
49 
13 
 
15 
18 
9 
 
36 
43 
21 
 
 
0.257 
 
 
1.25 
 
 
0.75-2.09 
 
 
0.38 
 In the model 3 which included all background, TB disease and treatment factors together, 
HIV and hypoalbuminemia were significant and thus predisposing the patients to drug 
induced liver injury. Other factors were not statistically significant.  
Subgroup analyses 
Subgroup analyses were done on significant variables. For example, HIV positive patients are 
more predisposed to have extensive disease. So the question is, whether HIV infection is 
confounding the relationship between disseminated disease and occurrence of DILI. Hence 
the following subgroup analyses were done to understand HIV and disseminated TB as 
independent risk factors. 
 
 
 
 
Alcohol intake 
Yes 
No 
 
266 
84 
 
76 
24 
 
34 
9 
 
79 
21 
 
0.65 
 
1.09 
 
0.42-2.8 
 
0.84 
Regimen 
Daily 
DOTS 
 
240 
110 
 
69 
31 
 
39 
4 
 
91 
9 
 
0.003 
 
1.96 
 
063-6.04 
 
0.24 
Extent 
Local 
Disseminated 
 
258 
92 
 
74 
26 
 
23 
20 
 
53 
47 
 
 
0.006 
 
 
1.35 
 
 
0.64-2.8 
 
 
0.42 
Table 25  HIV infection and disseminated disease 
 
The above chi-square table shows that HIV patients are predisposed to disseminated disease. 
55.5% of HIV TB was disseminated compared to 23 % non-HIV TB (OR 2.454, p value 
0.001, 95% C.I 1.84- 3.28). Hence subgroup analysis of relationship between extent of TB 
and DILI was examined in HIV negative patients. Even among HIV negative patients, 
disseminated disease predisposes to DILI 2.5 times more than localized disease (p value 
0.019, OR 2.592, 95% CI 1.14 – 5.87). 
Table 26 Extent and development of DILI among HIV negative patients 
Extent DILI (%) No DILI (%) Odds ratio C.I 
Local 16(59) 230(79) 2.592 1.14-5.87 
Disseminated 11 (41) 61 (21) p-value 0.019  
 
Similarly in patients with localized disease, presence of HIV infection was statistically 
associated with development of drug induced hepatitis (p value 0.016, OR 3.31 and 95% C.I 
1.19-9.21). 
 
 Local (%) Disseminated (%)    OR  95 %C.I 
HIV Present 32(44.5) 40(55.5) 2.454 1.84-3.28 
HIV Absent 246 (77) 72(23) p-value 0.001  
Table 27 HIV infection and development of DILI among patients with localized 
disease 
HIV DILI (%) No DILI (%) Odds Ratio 95 %C.I 
Yes 6(27) 26(10) 3.31 1.19-9.21 
No  16 (73) 230 (90) p-value 0.016  
 
HIV patients who have disseminated disease are mostly started on daily regimen. Hence the 
question was whether HIV infection is confounding the relationship between daily/thrice 
weekly and the occurrence of DILI. Hence both regimens were compared on HIV negative 
patients. Even among HIV negative patients, daily regimen was significantly predisposed 
more to ATT induced hepatitis compared to thrice weekly regimen(11% Vs 3%, p value – 
0.014, OR 4.18, 95% CI 1.23- 14.24).  
Table 28 Regimen and development of DILI among HIV negative patients 
Regimen DILI (%) No DILI (%) Odds Ratio 95 %C.I 
Daily 24(11) 191(89) 4.18 1.23-14.24 
DOTS 3 (3) 100(97) p-value 0.014  
 
Patients who have disseminated disease are more frequently started on daily regimen. Hence 
the question was whether disseminated disease was confounding the relationship between 
daily/thrice weekly regimens and the occurrence of DILI. Therefore the relationship between 
daily/thrice weekly regimens and DILI were compared in patients with localized disease. 
Even in those patients, daily regimen was an independent risk factor of ATT induced 
hepatitis (p value 0.007, OR 4.8 and 95 % C.I 1.39-16.56) 
Most of the patients on DOTS regimen were enrolled from secondary hospital of the 
Community health and department (CHAD hospital). The majority of TB in this setting was 
localized disease probably because CHAD is a secondary hospital. Therefore could referral 
bias, have influenced the relationship between localized disease and DILI.  Hence subgroup 
analysis of patients with localized disease was done to see whether daily regimen was a 
independent risk factor for ATT induced hepatitis.  Even then, daily regimen was a 
significant risk factor for ATT induced hepatitis (p value 0.007, OR 4.8 and 95% C.I 1.39-
16.56). 
Table 29 Regimen and development of DILI among patients with localized disease 
Regimen DILI(%) No DILI (%) Odds Ratio 95 %C.I 
Daily 20(12) 150(88) 4.8 1.39-16.56 
DOTS 3 (2.7) 108(97.3) p-value  0.007  
 
From the different subgroup analysis that addresses the issue of confounding, we conclude 
that HIV infection, disseminated disease and daily regimen were independent risk factors for 
developing ATT induced hepatitis. 
Predictive scoring system 
We also propose a scoring system from our study so that patient at risk can be identified early 
before initation of treatment. The scoring system was derived based on the significant risk 
factors for predicting DILI. Scores were given according to the odds ratio of the significant 
risk factors in the multivariate logistic regression analysis. HIV infection, chronic liver 
disease, daily treatment regimen, extent of tuberculosis, hypoalbuminemia and female gender 
are the risk factors included in the scoring system. The risk factors along with their scores are 
summarized as below.  
 Table 30 Predictive scoring system based on risk factors for DILI 
Risk factors for DILI Score 
HIV infection 3 
Chronic liver disease 4 
Daily treatment Regimen 2 
Extent of tuberculosis(disseminated) 2 
Hypoalbuminemia (S.albumin < 3.5 g/dl) 2 
Female gender 2 
 
Significance of the scoring system was calculated using Receiver Operator 
Characteristics(ROC) curve.  
 
    Fig.13 ROC curve for the predictive scoring system 
 
Area under the curve – 0.728 
Standard error – 0.037 
Confidence interval – 0.65 to 0.80 
Table 31 Summary of sensitivity and specificity for predictive score 
Score Sensitivity Specificity 
2.5 0.907 0.386 
4.5 0.744 0.669 
5.5 0.674 0.694 
6.5 0.395 0.826 
8.5 0.209 0.900 
10.5 0.093 0.980 
12.5 0.047 0.997 
 
The area under the curve for the above mentioned scoring system was calculated to be 0.728 
which indicates this predicve score is a fairly good score for predicting DILI. The sensitivity 
and specificity for individual scores were calculated be plotting the area under the curve  as 
mentioned above in table 31. A total score of 5 and above predicts DILI with the sensitivity 
of 74% and specificity of 67%. However this scoring system has to be validated by the 
prospective studies. 
 
  
Clinical Profile of patients with drug induced liver injury (DILI) 
 
Out of 43 patients who developed drug induced liver injury, 20 patients were males. 24 
patients had disseminated disease whereas 19 patients had local disease.  
Among 43 patients, 39 patients were on daily ATT and only 4 patients on intermittent thrice 
weekly DOTS regimen.  
 
Fig.14 : Gender distribution of the patients with ATT induced hepatitis 
23
20
18.5
19
19.5
20
20.5
21
21.5
22
22.5
23
23.5
Male Female
SEX
Frequency
  
Fig  15:  Extent of tuberculosis  among patients with ATT induced hepatitis.    
Clinical Features  
Vomiting was the most common symptom seen in 58.1% of patients of patients with 
drug induced hepatitis followed by jaundice in 30.2 % of patients. Other symptoms in the 
order of frequency were fever, pruritis, nausea and abdominal pain. However 7 patients 
(16.3%) were asymptomatic and diagnosed based on enzyme elevation more than 5 times.  
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Table 32: Symptoms profile of patients with DILI 
Symptoms  Frequency  Percentage (%)  
Fever  6  14  
Vomiting  25  58.1  
Abdominal pain  2  4.7  
Jaundice  13  30.2  
Pruritis  3  7  
Nausea  2  4.7  
Dyspnea  1  2.3  
Asymptomatic  7 16.3 
 
On examination, icterus was observed in 28 patients (65%) followed by hepatomegaly in 2 
patients. Signs of decompensation were seen in 4 patients. Other patients did not have any 
findings on examination.  
Table33  Signs of Hepatic Decompensation in patients with DILI  
 Number  Percentage 
Ascites  2  4.7  
Encephalopathy  3  7.0  
Current Regimen 
Patients who developed drug induced liver injury were on the following regimen before they 
developed hepatotoxicity 
 Isoniazid, Rifampicin, Pyrazinamide and Ehtambutol (HRZE) in 41 
patients(95.3%) 
 Isoniazid, Rifampicin, Pyrazinamide and Ehtambutol  and 
Streptomycin(HRZES) in 1 patient (2.3%) 
 MDR regimen in 1 patient (2.3%) 
As presented earlier 90.7% of patients with DILI were on daily TB treatment regimen 
(39/43) 
Alternate regimen was started after development of DILI as follows: 
 Amikacin, Levofloxacin and Ethambutol (ALE)in 30 out of 43 patients 
 Isoniazid, Pyrazinamide, Ethambutol and Levofloxacin (HZEL) in 4 patients. 
This was started in patients with drug induced cholestasis probably due to 
Rifampicin. 
Onset of DILI after initiation of anti-tubercular drugs 
Drug induced liver injury was seen as early as first day till 153 days after initiation of anti-
tubercular drugs. Majority of patients (77%) developed drug induced liver injury within first 
2 months. 20 patients developed DILI within 2 weeks followed by 13 patients from 2 weeks 
to 2 months. 
 
 Fig.16 : Time to onset of ATT induced hepatitis  
The mean time duration for normalization of liver function was 22 days ranging from 3 to 81 
days.  
Type of hepatitis and severity 
 
Type of hepatitis was classified as cholestatic, icteric and anicteric hepatitis. Icteric 
hepatitis was the most common type seen in 26 patients (60%) followed by cholestatic pattern 
in 11 (26%) and anicteric hepatitis in 6 patients (14%) and the order of frequency.  
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 Fig. 17 Types of hepatitis in patients with DILI 
Severity of hepatitis was according to WHO toxicity standards into mild, moderate and 
severe hepatitis. 15 patients (35%) had severe hepatitis. 13 patients (30%) had moderate 
hepatitis and 12 patients (28%) had mild hepatitis. 
 
Fig. 18 Severity of hepatitis 
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Outcome of patients with drug induced liver injury 
 Forty one patients were regular on treatment till the developed hepatotoxicity. 
Hospitalization was required for 39 patients(90.7%).Four of them needed ICU care, out of 
which 3 of them improved and one died. 36 patients had complete resolution(84%). Four 
patients had features of acute hepatic failure out of which 3 patients recovered.  All cause 
mortality was 4.7 % (2 patients). The causes of death were acute liver failure in one patient 
and pulmonary embolism in the other patient. 
 Rechallenge of anti-tubercular drugs 
There are three main approaches to reintroduction of first line drugs.  
 Reintroduction of full dose of one drug at a time preferably Rifampicin 
followed by Isonizaid and Pyrazinamide (according to ATS guidelines). 
 Reintroduction of escalating doses of one drug at a time (according to 
British Thoracic Society guidelines). 
 All three drugs at a time (full doses) 
Among 29 patients who were rechallenged, at least 1 drug was successfully rechallenged in 
28 patients.  All 3 hepatotoxic drugs were reintroduced successfully in full doses at the same 
time in 2 patients. Both of them had mild hepatitis.  Rechallenge by both ATS and BTS 
guidelines had similar successful rate. Rechallenge methods and their frequency were as 
follows: 
 One drug at a time in full dose (ATS guideline) -58.6% 
 One drug at a time in escalating dose (BTS guideline)-34.5% 
 All drugs-6.9% 
Isoniazid was the first drug rechallenged in 23 out of 31 patients which was followed by 
Rifampicin  in 8 patients. Rifampicin was not rechallenged in 2 patients in view of cholestatic 
picture most probably due to Rifampicin. Hence Levofloaxin was started   on those 2 
patients. 
 Successful Rechallenge                                                        
  
 All three drugs are succesully rechallenged in 5 patients. At least two drugs were 
rechallenged in 16 patients. Isoniazid was successfully rechallenged in 24 out of 28 patients 
and Rifampicin in 26 out of 29 patients.  Pyrazinamide successfully rechallenged in all 6 
patients 
Rechallenge hepatitis to isoniazid and rifampicin  developed in four and three patients 
respectively. 
Table 34 Various guidelines and rechallenge hepatitis 
 Rechallenge hepatitis  
Isoniazid Rifampicin Total rechallenge 
hepatitis 
ATS guidelines 2 out of 16 
(12.5%) 
2 out of 14 (14.2%) 4/30 (13.3 %) 
BTS guidelines 2 out of 11 
(18.2%) 
 1 out of 12 (8.3%) 3/23 (13 %) 
ALL three drugs at 
a time 
 None None None 
 
There was no apparent difference in the rates of rechallenge hepatitis between the two 
rechallenge regimens. Outcome of tuberculosis in patients with DILI 
 Fig. 19 Outcome of tuberculosis in patients with DILI 
8 patients with DILI had completed their treatment and were cured of tuberculosis. One of the 
patients who expired did not complete treatment. 18 patients are under treatment and 16 
patients had lost follow up. 
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Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tuberculosis remains as a major threat to developing countries like India despite availability 
of effective treatment which can cure most of the cases.  India and China account for 40 % of 
world’s total TB cases(2). One of the major reasons for discontinuing treatment is due to 
adverse reactions mainly drug induced liver injury (DILI).  Anti-tubercular drug induced liver 
injury not only leads to interruption of treatment but also increases the risk of developing 
multi drug resistant and extremely drug resistant tuberculosis.  However early identification 
of drug induced liver injury, starting the patients on alternate non hepatotoxic regimen and 
subsequent rechallenge if possible can prevent the above mentioned risks and decrease 
morbidity and mortality related to DILI. It is this background that this study was conducted to 
determine the incidence, risk factors, clinical course and outcomes of anti-TB drug induced 
liver injury. The overall goal of the study was (a) towards developing an appropriate 
screening strategy to predict DILI and (b) appropriate management strategy for DILI to 
improve outcomes of both liver injury and tuberculosis.  
Baseline characteristics 
In our cohort, majority of the patients were male (61%) and in the middle age group 
(81%).  45% had normal body mass index but a significant number of people (34%) were 
underweight. Few recent studies from India showed increased prevalence of tuberculosis 
among diabetics. In our cohort, diabetes was present in 35% of the patients of age more than 
35 years.  Mean HbA1c was 8.75 suggesting that uncontrolled diabetics were more 
predisposed to chronic infections like tuberculosis.  However more studies are needed to 
support this information. If so, there is a threat for increase in number of new patients 
diagnosed with tuberculosis due to increasing prevalence of diabetes mellitus in India. HIV 
infection was seen in 72 patients (18.3%) which is higher than reported in other Indian 
studies(54).   
Incidence of drug induced liver injury 
Incidence of drug induced liver injury in our study was 9.7% (CI 7-13.2%). The large 
study and narrow confidence intervals suggest that the incidence is fairly accurate. The 
incidence varies between different countries with lower incidence in western countries 
compared to developing countries like India. This study confirms the higher incidence of 
DILI in TB in our country.   
A meta analysis of 14 published studies (3) from western countries showed an 
incidence of 4.38%. Incidence of ATT induced hepatotoxicity from our study was 
comparable to the studies from Asian countries.  A Malaysian study published in Singapore 
Medical Journal by Marzuki et al showed an incidence of 9.7% (95% C.I  7-13.2%) similar to 
our study(57).  Incidence of ATT induced hepatitis was 16% according to a North Indian 
study by Sharma et al(16) and 10.5% according to a study by Deepak et al(54). The reason 
for higher incidence of ATT induced hepatitis in Asian countries is clearly unknown. Ethnic 
susceptibility and genetic polymorphisms may play a role in increased incidence of 
hepatotoxicity. While this may be the case, in the risk factor analysis we have attempted to 
explore the role of common acquired risk factors such as under nutrition, extensive TB and 
HIV infection in the development of DILI in our setting. 
In our study, 279 patients were on daily regimen and 114 patients were on intermittent 
thrice weekly DOTS regimen. Incidence of ATT induced hepatitis was 14% (95% C.I 7.9% - 
22.4%) among daily regimen group as compared to 3.5% (95% C.I 2.4% - 4.8%)in DOTS 
regimen group. This study confirms the lower incidence of DILI in DOTS that has been 
reported in earlier studies. The lower incidence in DOTS regimen group was similar to a 
Chinese study by Shang et al(4). In that prospective study of 4304 patients who were on 
DOTS regimen, incidence of drug induced liver injury was 2.55%.  The majority of the 
patients who were on DOTS treatment were receiving treatment in the community hospital, 
had localized TB disease and lower rates of HIV infection. These too may have contributed to 
the lower incidence of DILI on DOTS. Another study from Tirupathi(58) showed a DILI 
incidence of 3.3% with DOTS. However another study from Hong Kong(59) did not 
confirmed this finding. This could have also been due to the high background rates of 
hepatitis B carrier status.  
Model of impact of DILI on TB treatment based on our study 
 
 
 
 
 
 
The significance of DILI is brought out in the above box which shows that if four 
hundred patients were diagnosed with tuberculosis, DILI develops in forty patients.  Four 
patients will develop acute liver failure and and one patient will die due to DILI. This model 
helps us understand the impact of DILI on TB treatment.  
All these indicate that significant effect on patients lives and public health importance of 
DILI on morbidity and mortality of tuberculosis.  
 
 
If 400 patients diagnosed with tuberculosis are started on TB treatment the 
following are the impacts of DILI 
- 40 patients develop DILI  
- Nearly all DILI patients require hospital admission  
- 4 patients will develop acute liver failure 
- 1 patient will die of DILI 
- Nearly all patients will require modification of TB regimen 
- The impact on treatment failure, relapse and drug resistance is 
not known 
Predictors of liver injury 
Bivariate analysis in this study showed that hypoalbuminemia , HIV infection,  
underlying chronic liver disease,  disseminated disease and daily regimen were significantly  
associated with the development of DILI. These findings are consistent to other published 
studies and confirm these findings.  
HIV and disseminated disease 
 Among the significant risk factors, disseminated disease was significantly associated 
with developed DILI with odds ratio of 1.769 and p value 0.006. Forty seven percent of 
patients in the DILI group had disseminated disease when compared to 26% of those who did 
not develop DILI . Other significant risk factor was the presence of HIV infection. 36% of 
patients who developed DILI were HIV positive compared with 16% of patients with HIV 
infection in those who did not develop DILI with odds ratio of 2.84 and p value of 0.002.  In 
our cohort, HIV patients were more predisposed to disseminated disease (p value 0.006) 
which is already known(60)(61,62).  Hence further subgroup analyses were done to 
understand whether either factor was confounding the relationship of other factor to the 
occurrence of DILI. HIV infection was still significant even in patients with localized disease 
(p value 0.016, OR 3.31).  Also disseminated disease was a significant risk factor for 
development of DILI even in HIV negative patients ( p value 0.019, OR 2.59). Hence we can 
conclude that both HIV infection and disseminated disease were independent risk factors for 
development of DILI.  
Chronic liver disease 
Presence of chronic liver disease was a significant risk factor for development of DILI 
(p value 0.004, OR 4.72). However there were only 14 patients with underlying chronic liver 
disease in our study.  Hence while interpreting these conclusions, the limitation of the smaller 
number should be kept in mind.  This findings is consistent with the literature regarding the 
higher rates of hepatoxicity in underlying chronic liver disease (21,22). In view of the high 
risk of DILI with underlying chronic liver disease, we recommend that these patients may be 
started on non-hepatotoxic regimen initially and subsequently challenged with first line 
hepatotoxic drugs one at a time. 
Hypoalbuminemia 
The other significant predictor of liver injury was hypoalbuminemia (p value 0.045, 
OR 1.92). However this may be a confounding factor since other significant factors like HIV 
infection, disseminated disease and underlying chronic liver disease are known to cause 
hypoalbuminemia.  This study confirms the earlier findings that hypoalbuminemia is a risk 
factor for DILI (29)(16). 
DOTS versus daily regimen 
The single most risk factor after chronic liver disease for development of DILI from 
our study was daily regimen (p value 0.003, OR 4.469).  Fourteen percent (95% C.I 2.4%-
4.8%) of patients on daily regimen developed DILI when compared to 3.5% (95% C.I 7.9% - 
22.4%) patients on DOTS regimen. This is the only significant modifiable risk factor. 
Patients at higher risk of DILI can be potentially shifted to thrice daily DOTS regimen so as 
to reduce the risk of DILI. We also did subgroup analyses among HIV negative patients and 
those with localized disease. Even among HIV negative patients daily regimen was a 
significant risk factor for development of DILI.  
The reason why DOTS regimen had lower rates of hepatotoxicity despite similar 
doses per kilogram body weight  is  unknown. The difference between pharmacokinetics of 
daily therapy and DOTS in relation to liver, is the sustained higher level of drug 
concentrations in daily therapy. Therefore the toxicity appears to be time dependent 
(adequate concentration sustained over time) rather than concentration dependent. Similar 
differences are seen in aminoglycosides induced nephrotoxicity with divided daily dose 
compared to single daily dose(63).  
In an Indian study (31) published by Mandal et al in 2012, administration of daily 
regimen predisposed the patients more to drug induced liver injury as compared to 
intermittent DOTS regimen (7.5% versus 2.32 %). This study included only patients with 
sputum positive pulmonary tuberculosis and was followed only till completion of intensive 
phase. Both regimens had equal sputum conversion rate at the end of intensive phase. 
However default rate was more in the DOTS group (9.3% versus 5%). Given the rates of 
DILI in both regimen groups, it is clear that DOTS regimen is associated with lower rates of 
hepatotoxicity.  
From our study, DOTS regimen was be considered as a treatment option in patients 
with high risk of developing DILI. However in our study we have not yet obtained data on 
outcomes of tuberculosis including relapse and drug resistance on long term follow up of our 
patients. WHO is currently advocating daily treatment regimen for tuberculosis because of 
more rapid sterilization ( culture negativity) and lower rates of relapse(64). However the 
treatment trials comparing the daily and DOTS regimen as well as the clinical care guidelines 
have underemphasized the importance of the drug toxicity of DILI. Our study shows that 
patients on daily regimen have a 4.5 times greater risk of DILI requiring treatment 
modification, risk of acute hepatic failure and death. The impact of DILI on the overall 
clinical outcomes of tuberculosis is as a yet unclear.  
 
 
 
Model of impact of intermittent DOTS on DILI based on this study.  
 
 
 
 
 
 
Our study shows that if 400 patients are started on TB treatment, we can prevent 26 
cases of DILI with DOTS therapy as seen above. However the impact of this strategy on 
treatment efficacy and relapse rates needs further study. It appears that daily treatment 
regimens are a double edged sword. They have faster sterilizing rate, lower relapse and drug 
resistance but higher hepatoxicity. On the other hand intermittent DOTS regimen are better 
tolerated but have relatively worse TB outcomes. Therefore we suggest the reevaluation of 
DILI on the impact of TB treatment and potential benefit of DOTS in reducing DILI.  
Non significant risk factors 
Other factors such as gender, age and body mass index reported in earlier studies were 
not significantly associated with development of DILI. In the study published by Singla et al, 
significant risk factors for development of DILI included age more than 35 years and mid 
arm circumference < 20 cm. In another study by Pande et al, one of the risk factors associated 
with development of DILI was older age. In another study which was recently published by 
Pore et al, female gender was significantly associated with development of DILI.  In the 
multivariate analysis of our study, female gender on analysis showed a p value of 0.09 but the  
If 400 patients diagnosed with tuberculosis and started on DOTS treatment, 
 14  patients will develop DILI   
None will develop acute liver failure  
No deaths will occur due to DILI 
The comparative impact on TB cure, relapse and   drug resistance is unclear 
 
“26 CASES OF DILI WILL BE PREVENTED AMONG 400 PATIENTS 
STARTED ON DOTS IN COMPARISON TO DAILY REGIMNE” 
 
Odds ratio was of 1.97 indicating that it may be a significant risk factor for predicting DILI.  
There might be a gender predisposition to develop DILI but this was definitely overweighed 
by other risk factors.  Cytochrome P450 (CYP) 3A4 is expressed  at higher levels in women 
which can result in more toxic intermediates. A prospective study from Taiwan (2014) 
compared 355 TB patients with 475 healthy subjects(65). Eight single nucleotide 
polymorphisms of PXR gene were performed since PR gene controls CYP3A4 expression. 
This study showed PXR influences the susceptibility to tuberculosis with the increased risk 
among females..  
Mutivariate logistic regression analysis 
Multivariate logistic regression analysis was done based on three different models as 
described above in the results section. Analyzing 3 models separately helped us understand 
the influence of interacting risk factors for development of drug induced liver injury.  
Chronic liver disease, hypoalbuminemia, HIV infection and daily regimen were the 
independent risk factors for developing drug induced liver injury.  Disseminated disease was 
already known as a significant risk factor and similarly found in our bivariate analysis for 
development of DILI (p value 0.006).  The limited sample size and the interactions between 
disseminated TB, HIV infection and hypoalbuminemia may have diminished the influence of 
disseminated TB in the logistic regression analysis. Hence disseminated disease cannot be 
excluded from the list of significant risk factors.  Thus we suggest careful monitoring of 
patients started on anti-tubercular drugs in the presence of chronic liver disease, 
hypoalbuminemia, HIV infection, disseminated TB and patients who are on daily TB 
treatment regimens.  
The genetic  predisposition of  the patients to drug induced liver injury is well known 
based on recent studies(38,45,48). The clinical predictors of DILI in our study emphasized 
the role of acquired risk factors (HIV infection, disseminated tuberculosis and low albumin).  
What we observed from our study was that the combination of acquired risk factors 
predisposed the patients to DILI rather than a single risk factor. In practice this means that a 
patient who has disseminated TB and HIV or disseminated TB with undernutrition is at 
substantially higher risk of developing DILI. It does not seem to be an individual risk factor, 
but rather a combination of risk factors that renders the liver vulnerable to injury. The reason 
why these risk factors such as HIV infection, hypoalbuminemia, disseminated disease in 
combination predisposes to hepatotoxicity even in the absence of  underlying liver disease is 
not clear. We suggest that the combination of these risk factors may lead to either : 
a)increased  vulnerability of hepatocytes to normal TB drug metabolite levels or b) altered 
metabolism of TB drugs leading to higher concentration of hepatoxic metabolites. This 
hypothesis is consistent with clinical experience that patients can tolerate full rechallenge of 
all hepatotoxic drugs once their general clinical condition has improved. In summary, there 
appears to be an inherent succeptibility of the state of advanced tuberculosis to the 
development of DILI, the mechanism of which is at yet unclear. 
Predictive scoring for development of DILI 
According to the predictive score for development of DILI as described above, the 
sensitivity and specificity for the score of 5 and above was 74% and 67% respectively.   
 
 
 
 
 
 
Table 34 Scoring system 
Risk factors for DILI Score 
HIV infection 3 
Chronic liver disease 4 
Daily treatment Regimen 2 
Extent of tuberculosis 2 
Hypoalbuminemia (S.albumin < 3.5 g/dl) 2 
Disseminated disease 2 
 
Total Score of > 5 predicts DILI with sensitivity of 74% and specificity of 67% 
Based on the above mentioned scoring system, DILI can be predicted with a sensitivity of 
74% ( ie. Three out of 4 patients who will develop DILI can be identified before starting 
treatment). According to the scoring system, if the patient has HIV infection or chronic liver 
disease in combination of any one risk factor (hypoalbuminemia, disseminated disease, daily 
regimen and female gender), there is high risk for development of DILI. In the absence of 
HIV infection and chronic liver disease, a combination of 3 other risk factors 
(hypoalbuminemia, disseminated disease, daily regimen and female gender), increases the 
risk of DILI. Therefore in the presence of chronic liver disease, those patients can be started 
on non-hepatotoxic regimen initially and subsequently challenged with first line hepatotoxic 
drugs one at a time.   
Based on the above scoring system we propose the following clinical rule for prediction of 
DILI before starting TB treatment. 
  
Although ATT induced hepatotoxicity is a major public health problem, there is no prediction 
rule for clinical practice. We suggest that the application of this scoring system before 
initiating TB treatment can reduce the risk of DILI.  This prediction rule requires validation 
in further clinical studies. 
Profile of patients who developed DILI 
43 patients developed DILI out of which 23(53%) patients were male and 24(45%) 
had disseminated disease.  One patient out of 43 patients developed DILI was on MDR 
regimen who was successfully rechallenged after withdrawing the pyrazinamide, the most 
probable culprit drug.  Most of the patients (76.7%) developed DILI within first 2 months 
with 53% of patients developing DILI within first 2 weeks. Thus we suggest careful clinical 
and biochemical monitoring during first 2 months in patients with clinical risk factors. 
However 10 out of 43 patients developed DILI even after 2 months.  
Vomiting and jaundice are the common symptoms observed in those patients.  16% of 
patients were asymptomatic and diagnosed was based on deranged liver function tests.  Those 
patients developed DILI even after 2 months which suggests that this reflects true drug 
Proposed Clinical rule for prediction of DILI (based on scoring system) 
Situations of high risk of DILI 
1. Chronic liver disease + any one risk factor (low albumin or HIV 
infection or disseminated disease or female gender). 
2. HIV + any one risk factor (low albumin or chronic liver disease or 
disseminated disease or female gender). 
3. Low albumin+ Disseminated disease+ female gender (In patients 
who are HIV negative and no chronic liver disease). 
In all above mentioned situations initiation of low toxicity DOTS regimen can be 
considered 
induced liver injury rather than hepatic adaptation. The most common type of hepatitis was 
icteric hepatitis seen in 26 patients(60%). 15 patients (35%) had severe hepatitis with enzyme 
elevation more than 400 IU.  We also did subgroup analysis on patients who developed 
severe hepatitis. None of the factors analyzed except underlying chronic liver disease were 
found to be significant risk factor for developing severe hepatitis. Most of had complete 
resolution of liver functions after withdrawal of offending drugs. Low mortality rate (4.3%) 
was seen among patients who developed DILI. Acute liver failure was seen in 4 patients with 
one patient succumbing to the illness. Hence early identification can decrease morbidity and 
mortality associated with DILI. 
Rechallenge of anti-tubercular drugs 
Isoniazid was the first drug rechallenged followed by rifampicin in most of the 
patients. Pyrazinamide was rechallenged only in 6 patients which was successful in all 
patients. Hence we suggest that whenever possible, rechallenging the patients with 
pyrazinamide may be attempted at escalating doses according to British Thoracic Society 
guidelines.  Among various rechallenge methods, introducing one drug at a time in full dose 
according to American thoracic society guidelines was observed in 58.6% of patients. Among 
29 patients who were rechallenged, atleast 1 drug was successfully rechallenged in 28 
patients (96.5%).  Two patients were rechallenged with all 3 drugs at a time in full doses. 
Both of them had mild DILI and did not develop rechallenge hepatitis. Hence we suggest 
rechallenge of all 3 drugs can be attempted in patients with mild hepatitis in absence of 
clinically significant risk factors. 
A recent study published by Zuberi et al from Karachi(66) showed no significant difference 
between ATS and BTS guidelines(p value <0.7). However ATS guideline was easier to 
follow.  Another study from AIIMS(53) compared three different methods of ATT drugs 
reintroduction which showed no significant difference between the three groups. 
Rechallenge hepatitis to Isoniazid and Rifampicin was seen in four and three patients 
respectively.  Different methods of rechallenge were compared with rechallenge hepatitis 
(Refer table 34). The rates of rechallenge hepatitis were similar in patients who were 
rechallenged according to both ATS and BTS guidelines(13.3% Vs 13%). Our results are 
consistent with the published literature that there is a lack of difference in risk of rechallenge 
hepatitis between the two rechallenge regimens.  
Our suggestions regarding rechallenge regimens based on these results are: 
 Rechallenge according to ATS guidelines is safe and acceptable. Patients with chronic 
liver disease should be rechallenged with escalating drug doses according to BTS 
schedule with minimum number of hepatotoxic drugs. 
 Patients with asymptomatic DILI can probably be rechallenged with all three 
hepatotoxic drugs including Pyrazinamide. However we suggest that rechallenge with 
Pyrazinamide can be done with escalating drug doses. 
Limitations for our study 
Our study was a hospital based prospective study from a tertiary hospital in South 
India. We studied on incidence, clinical predictors of DILI, profile of patients with DILI, 
outcome of hepatitis and tuberculosis including rechallenge of first line drugs. Very few 
prospective studies have been done before from India with such a sample size covering all 
these aspects.  Our study has few limitations. We have not completed our sample size and we 
are planning to continue this study. Another limitation is the significant number of patients 
(32%) who had lost to follow up. We are planning to follow up those patients through 
telephone subsequently.  
Future work and research 
The predictive scoring system proposed from our study needs to be validated by a 
well designed prospective study. Further follow up of patients with DILI is being planned to 
assess relapse, default rate and drug resistance. Genetic predisposition also seems to play a 
role in drug induced liver injury apart from clinical risk factors and the role of NAT2 
polymorphisms in the Indian setting needs further study. More studies are required in this 
area so that we can derive a score based on both clinical and genetic risk factors that can 
predict DILI before initiation of treatment. If the state of disseminated TB increases 
vulnerability of the liver to drug induced hepatitis, the role of nutritional and other 
hepatoprotective regimens in reducing the risk of DILI needs further study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
  
 
 
 
 
 
 
 
 
Conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Incidence of anti-tubercular drug induced hepatitis from our study was 9.7% (95% C.I 
7-13.2%). The high incidence of DILI associated with TB treatment emphasizes the 
public health importance of this side effect in India. Intermittent DOTS regimen was 
associated with a DILI rate of 3.5% (95% C.I 2.4%-4.8%) compared to the rate of 
14% (95% C.I 7.9-22.4%) with daily treatment regimen. This confirms a substantially 
lower rate of DILI in DOTS treatment compared to daily TB treatment regimen. 
  HIV infection (OR 2.84, p value 0.002, 95% C.I 1.42 – 5.67), daily regimen (OR 
4.46. p value 0.003, 95% C.I 1.55 – 12.81),  disseminated disease (OR 1.769, p value 
0.006, 95% C.I 1.23-2.55),  hypoalbuminemia ( OR 1.92, p value 0.045, 95% C.I 1.01 
– 3.68) and chronic liver disease (OR 4.72, pvalue 0.004, 95% C.I 1.5-14.82) were 
independent risk factors for development of drug induced liver injury.  The results 
emphasize the importance of acquired risk factors in development of drug induced 
liver injury. A prediction score based on the above risk factors is suggested to identify 
patients who will develop DILI. A score of > 5 predicts DILI with a sensitivity and 
specificity of 74% and 67%. The application of this score in clinical practice can 
reduce risk of DILI. In patients with high risk of DILI identified by the scoring 
system, DOTS thrice weekly regimen can provide an alternate treatment strategy to 
reduce DILI risk. Further work is needed to validate the predictive scoring system 
derived from our study.  
 Mortality rate seems to be low (4.3%) among patients who developed DILI. Four 
patients (9.3%) developed acute liver failure. Most patients (84%) of patients had 
complete resolution after discontinuation of offending drugs. 
 At least one drug was rechallenged successfully in 96.5% patients. Rechallenge 
hepatitis to isoniazid and rifampicin developed in 4(14%) and 3 patients (10%) 
respectively.  
 Rechallenge by both ATS and BTS guidelines had similar successful rate. 
Rechallenge  according to ATS guidelines with full dose of one drug at a time may be 
recommended for most cases of DILI. However British thoracic guideline for 
rechallenge with escalating dose of each drug sequentially administered, may be 
preferred in those with chronic liver disease and for pyrazinamide rechallenge.  
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APPENDIX I: INFORMED CONSENT                                             
DOCUMENT 
  Date: 
I  …………………………….( Participant’s name), Hosp no…………… have fully read and 
understood the participant’s information sheet as given above. 
By signing this form I agree that 
(1) I understand that the purpose of this study is to improve the quality of medical 
care and that my involvement may not benefit me. 
(2) I have been made aware of the procedures involved in the study and the expected 
inconvenience, risk, discomfort or potential side effects as far as they are currently 
known by the researcher. 
(3) My participation in this study is fully voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being 
affected. 
(4) I understand that my identity will not be revealed in any information released to 
third parties or published. 
(5) I will not restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s) 
I do hereby agree to take part in this study. 
Patient           Name                       Signature                            Date 
(or Thumb impression) of the Subject/Legally Acceptable Representative 
Investigator   Name                      Signature                             Date 
Witness         Name                       Signature                            Date 
APPENDIX II: PATIENT INFORMATION 
SHEET 
1. Study title 
PREDICTORS, OUTCOME, PROFILE OF ANTI-TUBERCULOSIS DRUG INDUCED 
HEPATITIS – A prospective nested case- control study in a South Indian tertiary hospital. 
2. Principal Investigator  Dr. Selvin Sundar Raj M 
3. Contact address    
Department of General Medicine Uni1, 
Christian Medical College, Vellore 632 004, India 
 Email: selvinsr@gmail.com  
Tel. + 91 416 2282089 
This study is a research project conducted in CMC Vellore, Outpatients and In-patients of 
Department of General Medicine and DOTS clinic (CHAD), CMC Vellore. You know that 
you have been diagnosed to have tuberculosis and started on treatment for the same. A 
proportion of patients say around 12 % develop jaundice as a complication of TB treatment. 
This study aims to study the clinical and genetic risk factors for TB drugs related 
jaundice. 
If you decide to participate in the study, you will be asked to give around 10 ml of blood 
collected from a vein near your elbow. This is the only invasive procedure that you will be 
subjected to.   
All precautions necessary will be taken to avoid any complications that may arise due to the 
venipuncture.  Your arm  will be cleaned with spirit and left to dry. Puncture will be made 
using a needle attached to a disposal syringe.Compression will be applied for 2 minutes to 
ensure that bleeding has stopped. This is all done as a one time process. Your treatment will 
not be altered based on any of the study results. 
By participating in the study you will not be made to incur any added expenses. There is no 
added risk of any kind for you by participating in this study. The information generated by 
this study may not directly benefit you at this time but may benefit the other patients in 
future. Any personal information about you that is collected as part of this study will be 
maintained strictly confidential. 
If you have any queries or problems you can contact the principal investigator at the above 
address.  If you choose not to participate, it will not affect your treatment in any way. 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX III: Patient Enrollment Form 
 Consent taken: Yes/ No             Patient sent to VCTC: Yes/No 
Name:                         Age:             Sex:              Study no: 
Contact No: 1)                     2) 
Address: 
Hospital No:                   
Diagnosis:    
1)Sputum  +ve Pulmonary  2)Sputum negative  pulmonary  3)Pleural  effusion   4) 
LN   5)TBM  6)TB peritonitis  7) Disseminated  8)TB spine  9)Miliary TB   10)GUTB   11) 
CNS TB(tuberculomas)   12) TB OM 13) synovitis   14)other 
Type of TB and extent:  
Basis of diagnosis of TB:      
1) Clinical    2) Radiological 3)Microbiological 4) Histopathological 5)Lab 
Date of diagnosis:                 Treatment started on: 
Regimen  
1) Daily   2) Category I       3) Category   II 
Drug doses:                                                                Drug frequency 1) Daily 2) thrice daily 
 
 
 
Risk factors: 
1) Site of TB  
1) Pulmonary 2) Pleural effusion 3) lymphadenitis 4) TB meningitis 5) TB peritonitis 6) 
Disseminated 
2) Extent of TB:       1) Local            2) Disseminated 
3) BMI  :                          Height :                       Weight:      : 
4) Underlying liver disease (details):1) alcoholic  2) hepatitis B    3)hepatitis C  4) None 
5) Past history of jaundice :  1) Yes         2) No 
6) Hypoalbuminemia :  
7) Alcoholic: 1)Never  2) Past   3 ) Current  
Amount         Frequency      Duration      (Months) 
1) Once a week     2) twice a week        3) thrice a week           4)>3 days a week  
5) Once a day         6) twice a day            7) thrice a day 
8) HIV status:      1)positive  2) negative 3)unknown 
9) Pregnancy: 
10) Diabetes Mellitus : Yes/No           HbA1c: 
Final patient category                                     A     / B /   C 
 
 
 
 
 
Proforma for ATT induced hepatitis 
Case no.         Name                            Hospital No.   Unique no. 
Contact No                                   Age                  Gender   1.Male   2.Female 
Place                                                 Basis of Diagnosis:  C     /   R       /     M    /      H    /    L 
Site of TB   
1)Sput +ve Pul  2)Sputneg pulm  3)Ple effus   4) LN   5)TBM  6)TB peritonitis  7) 
Diss  8)TBspine  9)Miliary TB   10)GUTB   11) CNS TB(tuberculomas)   12) TB OM 13) 
synovitis   14)other 
Extent of TB      1.Local               2.disseminated                               
Current Regimen 
Alternate Regimen 
Cohort/Presentation  1.Cohort        2.Presentation 
Date on initiation of ATT 
DILI Date                                              Time period after initiation of treatment (days): 
Normalization of LFT (days): 
Symptoms             
1.Fever      2.Vomiting     3.Abdominal pain     4.Jaundice   5.Rash      6.Others 
Signs   
1.Jaundice    2.Hepatomegaly(yes/no)      3.Signs of hepatic decompensation     4.Rash    
5.Others 
Signs of decompensation:  1) Nil 2)Ascites  3)Encephalopathy 4) bleeding 
Treatment regular        1.Yes      2.No 
Baseline     TB           DB            SGOT          SGPT            TP            Alb             Alk phos 
Maximum  TB          DB             SGOT          SGPT             TP           Alb           Alk phos 
 
Time duration for normalization of LFT (days): 
ATT restarted on:  
Drug Date Dose Successful 
    
    
    
 
Rechallenge method     1. One drug full dose         2. One drug escalating      3. All drugs 
Outcome of Hepatitis: 
Severity of hepatitis 1. Mild        2.Moderate         3.Severe         4.Others 
Type of hepatitis: 
1. Anicteric hepatitis       2.Icteric hepatitis       3.Cholestatic        4.Decompensation 
Requirement of hospitalizations      1.Yes         2.No 
ICU care                   1. Yes     2.No 
Severity of hepatitis:  
 a)complete resolution b)acute fulminant hepatitis  c)chronic hepatitis  d)Fatal 
All cause mortality at completion of treatment         1.yes       2.no              3.Unknown 
Number of first line drugs successfully reintroduced: 
Drugs successfully rechallenged                   Rechallenge hepatitis 1.  INH    2. RIF     3.PYZ 
Outcome  of tuberculosis 
Treatment completed -   1.Yes   2. No   3. Under treatment   4.Lost follow up    
Telephonic follow up 1. Not contactable 2. Treatment completed   3. Defaulted 
Cured of tuberculosis   1. Yes    2. No       3.Improved     4.Expired  
Duration of treatment (months)                               Final rechallenge regimen used 
 
